NCT02194322View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

January 31, 2002

Conditions
Healthy
Interventions
DRUG

BIBN 4096 BS - in single rising doses

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY